Oslo Cancer Cluster member Immunitrack has been awarded a grant from Eurostars to develop their prediction tool for cancer vaccines.
Immunitrack is a biotech company that develops software, which predicts immune responses and assesses new cancer vaccines.
Developing a new vaccine can be a lengthy and expensive process, with a high risk of failure. One key to success is being able to predict how the patient’s immune system will react, so drug developers can bring forth therapies that mobilize the immune system to fight the disease. Immunitrack’s tools can help developers predict the impact of a new drug on the patient’s immune system, before entering clinical trials.
Eurostars supports international innovative projects and is co-funded by Eureka member countries and the European Union Horizon 2020 framework programme. The funding will be used by Immunitrack over a 24-month period for the ImmuScreen Project, to develop a new prediction tool. It will both improve how cancer vaccines work and how to track patients’ immune responses.
“This Eurostar project will give additional momentum to the ongoing development of a best in class neo-epitope prediction tool, PrDx TM, by Immunitrack,” says Sune Justesen, CSO at Immunitrack.
Immunitrack will receive a total of approximately €750 000 from Eurostars, together with the Centre for Cancer Immune Therapy (CCIT), based in Herley, Denmark. CCIT aims to bridge the gap between research discovery and clinical implementation of treatments in the field of cancer immunotherapy.
“The collaboration with the Danish Cancer Center for Immune Therapy, is certainly an important step in validating and implementing PrDx, in the immune therapy treatment of cancer patients,” says Sune Justesen, CSO at Immunitrack.
Immunitrack will handle the software development, while CCIT performs the in vitro validation. The clinical validation will be carried out in melanoma patients. The results will help to characterize immune responses and help to understand why some tumours are immune to novel cancer vaccines.